Skip to main content

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Antidementiva im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Afzal S, Bojesen SE, Nordestgaard BG (2014) Reduced 25-hydroxyvitamin D and risk of Alzheimer’s disease and vascular dementia. Alzheimers Dement 10(3): 296–302

    Google Scholar 

  • Cooper C, Li R, Lyketsos C, Livingston G (2013) Treatment for mild cognitive impairment: systematic review. Br J Psychiatry 203: 255–264

    Google Scholar 

  • Hefner G, Brueckner A, Hiemke C, Fellgiebel A (2015) Therapeutic drug monitoring for patients with Alzheimer dementia to improve treatment with donepezil. Ther Drug Monit 37(3): 353–361

    Google Scholar 

  • Lange-Asschenfeldt C (2013) Vaskuläre Faktoren in der Pathogenese der Alzheimer-Krankheit. Nervenarzt 84(6): 732–737

    Google Scholar 

  • Monsell SE, Kukull WA, Roher AE et al (2015) Characterizing apolipoprotein E ε4 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal β-amyloid peptide plaques. JAMA Neurol 72(10): 1124–1131

    Google Scholar 

  • Nordström P, Religa D, Wimo A et al (2013) The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer’s disease. Eur Heart J 34(33): 2585–2591

    Google Scholar 

  • Porsteinsson AP, Drye LT, Pollock BG et al; CitAD Research Group (2014) Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 311(7): 682–691

    Google Scholar 

  • Schmidt R, Hofer E, Bouwman FH et al (2015) EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol 22(6): 889–898

    Google Scholar 

  • Schneider LS, Mangialasche F, Andreasen N et al (2014) Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med 275(3): 251–283

    Google Scholar 

  • Stinton C, McKeith I, Taylor JP, Lafortune L et al (2015) Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry 172(8): 731–742

    Google Scholar 

  • Tan MS, Yu JT, Tan CC et al (2015) Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis 43(2): 589–603

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lange-Asschenfeldt, C., Benkert, O. (2017). Antidementiva. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50333-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50333-1_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50332-4

  • Online ISBN: 978-3-662-50333-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics